Lastly, although LDL-C remains an important treatment target, other broader measures of atherogenic lipoprotein burden, such as non–HDL-C and apolipoprotein B, may be considered in hypertriglyceridemia according to recent guidelines.1,26. Here, APOB is linked to hypertriglyceridemia.